These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20581867)

  • 1. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
    Chakrabarty A; Rexer BN; Wang SE; Cook RS; Engelman JA; Arteaga CL
    Oncogene; 2010 Sep; 29(37):5193-203. PubMed ID: 20581867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
    Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
    Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
    Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
    PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
    Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
    Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG; Hosick HL; Ethier SP
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
    Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.